LEIDEN, NETHERLANDS, Jul 12 (MARKET WIRE) —
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces
today that it has signed a pharmaceutical development and manufacturing
contract with a new client, US-based The Medicines Company. The
undisclosed contract value will make a material contribution to OctoPlus’
annual revenues.
Under the contract terms, OctoPlus will perform process development and
clinical manufacturing for The Medicines Company related to MDCO-216
(ApoA-I Milano/phospholipid complex).
OctoPlus provides formulation development and clinical material
manufacturing services to biotech and pharmaceutical companies worldwide.
In addition to its expertise in formulation and manufacturing, OctoPlus
offers its clients drug delivery technologies for the development of
controlled release versions of existing or new drugs.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524
1071 or send an e-mail to Investor Relations at IR@octoplus.nl.
About OctoPlus
OctoPlus is a drug delivery company committed to the creation of improved
pharmaceutical products that are based on OctoPlus’ proprietary drug
delivery technologies and have fewer side effects, improved patient
convenience and a better efficacy/safety balance than existing therapies.
OctoPlus focuses on the development of long-acting, controlled release
versions of known protein therapeutics, other drugs, and vaccines on
behalf of its clients.
The clinically most advanced product incorporating our technology is
Biolex Therapeutics’ lead product Locteron(R), a controlled release
formulation of interferon alpha for the treatment of chronic hepatitis C.
OctoPlus licensed Locteron exclusively to Biolex in October 2008.
Locteron is being manufactured for Biolex by OctoPlus and is currently in
Phase IIb clinical studies.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the
pharmaceutical and biotechnology industries, with a focus on
difficult-to-formulate active pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol
OCTO. For more information about OctoPlus, please visit our website
www.octoplus.nl.
This document may contain certain forward-looking statements relating to
the business, financial performance and results of OctoPlus and the
industry in which it operates. These statements are based on OctoPlus’
current plans, estimates and projections, as well as its expectations of
external conditions and events. In particular the words “expect”,
“anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”,
“would”, “will”, “intend”, “believe” and similar expressions are intended
to identify forward-looking statements. We caution investors that a
number of important factors, and the inherent risks and uncertainties
that such statements involve, could cause actual results or outcomes to
differ materially from those expressed in any forward-looking statements.
In the event of any inconsistency between an English version and a Dutch
version of this document, the English version will prevail over the Dutch
version.
[HUG#1430917]
Click here for the press release in PDF:
http://hugin.info/137076/R/1430917/377483.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
All reproduction for further distribution is prohibited.
Source: OctoPlus N.V. via Thomson Reuters ONE
Copyright 2010, Market Wire, All rights reserved.